FOLD
Price
$8.16
Change
-$0.04 (-0.49%)
Updated
Oct 6 closing price
Capitalization
2.52B
29 days until earnings call
RARE
Price
$30.19
Change
-$1.02 (-3.27%)
Updated
Oct 6 closing price
Capitalization
2.91B
28 days until earnings call
Interact to see
Advertisement

FOLD vs RARE

Header iconFOLD vs RARE Comparison
Open Charts FOLD vs RAREBanner chart's image
Amicus Therapeutics
Price$8.16
Change-$0.04 (-0.49%)
Volume$4.24M
Capitalization2.52B
Ultragenyx Pharmaceutical
Price$30.19
Change-$1.02 (-3.27%)
Volume$1.32M
Capitalization2.91B
FOLD vs RARE Comparison Chart in %
FOLD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RARE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
FOLD vs. RARE commentary
Oct 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FOLD is a Hold and RARE is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 07, 2025
Stock price -- (FOLD: $8.16 vs. RARE: $30.19)
Brand notoriety: FOLD and RARE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: FOLD: 86% vs. RARE: 82%
Market capitalization -- FOLD: $2.52B vs. RARE: $2.91B
FOLD [@Biotechnology] is valued at $2.52B. RARE’s [@Biotechnology] market capitalization is $2.91B. The market cap for tickers in the [@Biotechnology] industry ranges from $103.3B to $0. The average market capitalization across the [@Biotechnology] industry is $2.05B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

FOLD’s FA Score shows that 0 FA rating(s) are green whileRARE’s FA Score has 0 green FA rating(s).

  • FOLD’s FA Score: 0 green, 5 red.
  • RARE’s FA Score: 0 green, 5 red.
According to our system of comparison, FOLD is a better buy in the long-term than RARE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

FOLD’s TA Score shows that 3 TA indicator(s) are bullish while RARE’s TA Score has 6 bullish TA indicator(s).

  • FOLD’s TA Score: 3 bullish, 5 bearish.
  • RARE’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, RARE is a better buy in the short-term than FOLD.

Price Growth

FOLD (@Biotechnology) experienced а +2.77% price change this week, while RARE (@Biotechnology) price change was -0.56% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.91%. For the same industry, the average monthly price growth was +14.77%, and the average quarterly price growth was +84.62%.

Reported Earning Dates

FOLD is expected to report earnings on Nov 05, 2025.

RARE is expected to report earnings on Nov 04, 2025.

Industries' Descriptions

@Biotechnology (+6.91% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RARE($2.91B) has a higher market cap than FOLD($2.52B). FOLD YTD gains are higher at: -13.376 vs. RARE (-28.239). FOLD has higher annual earnings (EBITDA): 33.1M vs. RARE (-435.33M). RARE has more cash in the bank: 477M vs. FOLD (231M). RARE has less debt than FOLD: RARE (36.3M) vs FOLD (443M). RARE has higher revenues than FOLD: RARE (610M) vs FOLD (571M).
FOLDRAREFOLD / RARE
Capitalization2.52B2.91B86%
EBITDA33.1M-435.33M-8%
Gain YTD-13.376-28.23947%
P/E RatioN/AN/A-
Revenue571M610M94%
Total Cash231M477M48%
Total Debt443M36.3M1,220%
FUNDAMENTALS RATINGS
FOLD vs RARE: Fundamental Ratings
FOLD
RARE
OUTLOOK RATING
1..100
5660
VALUATION
overvalued / fair valued / undervalued
1..100
56
Fair valued
64
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9699
PRICE GROWTH RATING
1..100
4983
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

FOLD's Valuation (56) in the Biotechnology industry is in the same range as RARE (64). This means that FOLD’s stock grew similarly to RARE’s over the last 12 months.

FOLD's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as RARE (100). This means that FOLD’s stock grew similarly to RARE’s over the last 12 months.

FOLD's SMR Rating (96) in the Biotechnology industry is in the same range as RARE (99). This means that FOLD’s stock grew similarly to RARE’s over the last 12 months.

FOLD's Price Growth Rating (49) in the Biotechnology industry is somewhat better than the same rating for RARE (83). This means that FOLD’s stock grew somewhat faster than RARE’s over the last 12 months.

FOLD's P/E Growth Rating (100) in the Biotechnology industry is in the same range as RARE (100). This means that FOLD’s stock grew similarly to RARE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
FOLDRARE
RSI
ODDS (%)
Bearish Trend 4 days ago
73%
Bearish Trend 4 days ago
78%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
75%
Bearish Trend 4 days ago
75%
Momentum
ODDS (%)
Bearish Trend 4 days ago
88%
Bullish Trend 4 days ago
79%
MACD
ODDS (%)
Bearish Trend 4 days ago
70%
Bullish Trend 4 days ago
77%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
77%
Bullish Trend 4 days ago
76%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
73%
Bearish Trend 4 days ago
82%
Advances
ODDS (%)
Bullish Trend 26 days ago
70%
Bullish Trend 4 days ago
78%
Declines
ODDS (%)
Bearish Trend 6 days ago
77%
Bearish Trend 6 days ago
81%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
76%
Bullish Trend 4 days ago
72%
Aroon
ODDS (%)
Bullish Trend 4 days ago
78%
Bearish Trend 4 days ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
FOLD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RARE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MSMIX32.400.05
+0.15%
NYLI WMC Value Investor Class
ARTGX27.770.02
+0.07%
Artisan Global Value Investor
SGFFX53.68N/A
N/A
Sparrow Growth A
WCMRX27.52N/A
N/A
WCM Focused International Growth Inv
BRSTX15.49N/A
N/A
MFS Blended Research Small Cap Eq R3